{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T23:48:16Z","timestamp":1775951296337,"version":"3.50.1"},"reference-count":18,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,7]],"date-time":"2025-12-07T00:00:00Z","timestamp":1765065600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["IDCases"],"published-print":{"date-parts":[[2026]]},"DOI":"10.1016\/j.idcr.2025.e02459","type":"journal-article","created":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T03:19:32Z","timestamp":1765423172000},"page":"e02459","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Pneumocystis jirovecii pneumonia in a human caused by long-term use of veterinary drug oclacitinib: A case report"],"prefix":"10.1016","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-6218-7581","authenticated-orcid":false,"given":"Keisuke","family":"Oshima","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryo","family":"Koyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Akimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshihiko","family":"Nishioki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomohito","family":"Takeshige","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junko","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daisuke","family":"Usuda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuhisa","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.idcr.2025.e02459_bib1","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2024.1414092","article-title":"Pneumocystis jirovecii pneumonia in non-HIV patients: need for a more extended prophylaxis","volume":"11","author":"Sauvat","year":"2024","journal-title":"Front Med"},{"key":"10.1016\/j.idcr.2025.e02459_bib2","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.jdin.2024.09.012","article-title":"Risk of infections during treatment with oral Janus kinase inhibitors in randomized placebo-controlled trials: a systematic review and meta-analysis","volume":"18","author":"Isufi","year":"2024","journal-title":"JAAD Int"},{"issue":"1","key":"10.1016\/j.idcr.2025.e02459_bib3","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1038\/s41392-021-00791-1","article-title":"The JAK\/STAT signaling pathway: from bench to clinic","volume":"6","author":"Hu","year":"2021","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.idcr.2025.e02459_bib4","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1146\/annurev-med-051113-024537","article-title":"The JAK-STAT pathway: impact on human disease and therapeutic intervention","volume":"66","author":"O'Shea","year":"2015","journal-title":"Annu Rev Med"},{"issue":"4","key":"10.1016\/j.idcr.2025.e02459_bib5","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/j.jaci.2021.08.009","article-title":"JAK inhibitors in the treatment of atopic dermatitis","volume":"148","author":"Chovatiya","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.idcr.2025.e02459_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.semarthrit.2022.152120","article-title":"Opportunistic infections associated with Janus kinase inhibitor treatment for rheumatoid arthritis: a structured literature review","volume":"58","author":"Winthrop","year":"2023","journal-title":"Semin Arthritis Rheum"},{"issue":"8","key":"10.1016\/j.idcr.2025.e02459_bib7","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0289827","article-title":"A retrospective evaluation of the effect of oclacitinib (Apoquel) administration on development of surgical site infection following clean orthopedic stifle surgery","volume":"18","author":"Motz","year":"2023","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.idcr.2025.e02459_bib8","first-page":"524","article-title":"Successful treatment of atopic dermatitis with the JAK1 inhibitor oclacitinib","volume":"31","author":"Haugh","year":"2018","journal-title":"Proc"},{"issue":"8","key":"10.1016\/j.idcr.2025.e02459_bib9","doi-asserted-by":"crossref","first-page":"812","DOI":"10.3390\/jof9080812","article-title":"Trends in the epidemiology of pneumocystis pneumonia in immunocompromised patients without HIV infection","volume":"9","author":"Xue","year":"2023","journal-title":"J Fungi"},{"issue":"3","key":"10.1016\/j.idcr.2025.e02459_bib10","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1111\/vde.12194","article-title":"Long-term compassionate use of oclacitinib in dogs with atopic and allergic skin disease: safety, efficacy and quality of life","volume":"26","author":"Cosgrove","year":"2015","journal-title":"Vet Dermatol"},{"issue":"4","key":"10.1016\/j.idcr.2025.e02459_bib11","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1111\/jvp.12101","article-title":"Oclacitinib (APOQUEL(\u00ae)) is a novel Janus kinase inhibitor with activity against cytokines involved in allergy","volume":"37","author":"Gonzales","year":"2014","journal-title":"J Vet Pharm Ther"},{"issue":"5","key":"10.1016\/j.idcr.2025.e02459_bib12","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.3390\/pharmaceutics14051001","article-title":"A comprehensive overview of globally approved JAK inhibitors","volume":"14","author":"Shawky","year":"2022","journal-title":"Pharmaceutics"},{"issue":"10","key":"10.1016\/j.idcr.2025.e02459_bib13","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1093\/rheumatology\/kez087","article-title":"A systematic review and meta-analysis of infection risk with small molecule JAK inhibitors in rheumatoid arthritis","volume":"58","author":"Bechman","year":"2019","journal-title":"Rheumatol"},{"issue":"3","key":"10.1016\/j.idcr.2025.e02459_bib14","first-page":"167","article-title":"Pneumocystis jirovecii pneumonia after initiation of tofacitinib therapy in rheumatoid arthritis: Case-based review","volume":"30","author":"Grigoropoulos","year":"2019","journal-title":"Mediterr J Rheuma"},{"key":"10.1016\/j.idcr.2025.e02459_bib15","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2014-204950","article-title":"Pneumocystis jiroveci pneumonitis complicating ruxolitinib therapy","volume":"2014","author":"Lee","year":"2014","journal-title":"BMJ Case Rep"},{"issue":"8","key":"10.1016\/j.idcr.2025.e02459_bib16","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1093\/ibd\/izae091","article-title":"Pneumocystis jirovecii pneumonia complicating use of upadacitinib in a patient with ulcerative colitis and primary sclerosing cholangitis: A case report","volume":"30","author":"Chin","year":"2024","journal-title":"Inflamm Bowel Dis"},{"issue":"3","key":"10.1016\/j.idcr.2025.e02459_bib17","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.resinv.2024.02.015","article-title":"Comparison of the outcomes of Pneumocystis jirovecii pneumonia in rheumatoid arthritis patients treated with and without biologics","volume":"62","author":"Ohmura","year":"2024","journal-title":"Respir Invest"},{"issue":"1","key":"10.1016\/j.idcr.2025.e02459_bib18","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.chest.2023.08.009","article-title":"Low-dose vs conventional-dose trimethoprim-sulfamethoxazole treatment for pneumocystis pneumonia in patients not infected with HIV: A multicenter, retrospective observational cohort study","volume":"165","author":"Nagai","year":"2024","journal-title":"Chest"}],"container-title":["IDCases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2214250925003166?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2214250925003166?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T23:09:54Z","timestamp":1775948994000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2214250925003166"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":18,"alternative-id":["S2214250925003166"],"URL":"https:\/\/doi.org\/10.1016\/j.idcr.2025.e02459","relation":{},"ISSN":["2214-2509"],"issn-type":[{"value":"2214-2509","type":"print"}],"subject":[],"published":{"date-parts":[[2026]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pneumocystis jirovecii pneumonia in a human caused by long-term use of veterinary drug oclacitinib: A case report","name":"articletitle","label":"Article Title"},{"value":"IDCases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.idcr.2025.e02459","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"e02459"}}